Compare IBEX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IBEX | ADCT |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 489.1M | 484.4M |
| IPO Year | 2017 | 2019 |
| Metric | IBEX | ADCT |
|---|---|---|
| Price | $29.56 | $4.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $35.00 | $7.50 |
| AVG Volume (30 Days) | 163.7K | ★ 711.0K |
| Earning Date | 05-18-2026 | 03-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 28.26 | ★ 44.90 |
| EPS | ★ 1.65 | N/A |
| Revenue | ★ $558,273,000.00 | $70,837,000.00 |
| Revenue This Year | $13.14 | $14.96 |
| Revenue Next Year | $5.67 | $1.06 |
| P/E Ratio | $17.65 | ★ N/A |
| Revenue Growth | ★ 9.77 | 1.84 |
| 52 Week Low | $21.64 | $1.05 |
| 52 Week High | $42.99 | $4.80 |
| Indicator | IBEX | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 37.95 | 57.66 |
| Support Level | $27.70 | $3.25 |
| Resistance Level | $30.63 | $4.32 |
| Average True Range (ATR) | 1.01 | 0.25 |
| MACD | 0.20 | -0.01 |
| Stochastic Oscillator | 67.80 | 51.19 |
IBEX Ltd delivers innovative business process outsourcing (BPO), smart digital marketing, online acquisition technology, and end-to-end customer engagement solutions to help companies acquire, engage, and retain valuable customers. It is an end-to-end provider of technology-enabled customer lifecycle experience (CLX) solutions to optimize customer acquisition, engagement, expansion, and experience for its clients. IBEX operates through the Business process outsourcing segment. Its services cover three areas: Digital and omni-channel Customer Experience (ibex Connect), Digital Marketing and E-Commerce (ibex Digital) and Digital CX surveys and analytics (ibex CX). It caters to a broad range of industries, such as telecommunications, cable, financial services, and healthcare.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).